陈茵婷 - 中山大学 - 孙逸仙纪念医院

个人简介

陈茵婷，中山大学孙逸仙纪念医院消化内科副主任医师、硕士生导师。2006年中山大学临床医学系本科毕业，2011年获得中山大学内科学医学博士学位。毕业后在中山大学孙逸仙纪念医院消化内科工作至今。科研工作方面主要从事消化道肿瘤转移、化疗耐药及靶向治疗研究，2013年评为中山大学孙逸仙纪念医院 “逸仙优秀医学人才”。

研究领域

消化系统疾病的诊断与治疗

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

[1] Chen Y#, Lian G#, Ou G#, Yang K, Chen J, Li H, Chen S, Li J, Zeng L*, Huang K*. Inverse association between Bmi-1 and RKIP affecting clinical outcome of gastric cancer and revealing the potential molecular mechanisms underlying tumor metastasis and chemotherapy resistance. Gastric Cancer, 2016, 19(2):392-402. (IF 4.404) [2] Chen Y, Lian G, Liao C, Wang W, Zeng L, Qian C, Huang K*, Shuai X*. Characterization of polyethylene glycol-grafted polyethylenimine and superparamagnetic iron oxide nanoparticles (PEG-g-PEI-SPION) as an MRI-visible vector for siRNA delivery in gastric cancer in vitro and in vivo. J Gastroenterol, 2013, 48(7):809-821. (IF 4.414) [3] Chen Y#, Lian G#, Zhang Q, Zeng L, Qian C, Chen S, Huang K*. Overexpression of Bmi-1 induces the malignant transformation of gastric epithelial cells in vitro. Oncol Res, 2013, 21(1):33-41. (IF 3.957) [4] Chen Y, Wang W, Lian G, Qian C, Wang L, Zeng L, Liao C, Liang B, Huang B, Huang K*, Shuai X*. Development of an MRI-visible nonviral vector for siRNA delivery targeting gastric cancer. Int J Nanomedicine, 2012, 7:359-368. (IF 4.32) [5] Chen Y, Huang K*, Li X, Lin X, Zhu Z, Wu Y. Generation of a stable anti-human CD44v6 scFv and analysis of its cancer-targeting ability in vitro. Cancer Immunol Immunother, 2010, 59(6):933-942. (IF 4.846) [6] Li J#, Chen Y#, *, Zeng L#, Lian G, Chen S, Li Y, Yang K, Huang K*. A nanoparticle carrier for co-delivery of gemcitabine and small interfering RNA in pancreatic cancer therapy. Journal of Biomedical Nanotechnology. (2015) (IF 3.929) [7] Chen S#, Chen Y#, Zeng L#, Zhang Q, Lian G, Li J, Yang K, Huang C, Li Y, Chu Z*, Huang K*. Bmi1 combines with oncogenic KRAS to induce malignant transformation of human pancreatic duct cells in vitro. Tumour Biol, 2016, 37(8):11299-11309. (IF 2.926) [8] Zeng L#, Li J#, Li J#, Zhang Q, Qian C, Wu W, Lin Z, Liang J, Chen Y*, Huang K*. Effective Suppression of the Kirsten Rat Sarcoma Viral Oncogene in Pancreatic Tumor Cells via Targeted Small Interfering RNA Delivery Using Nanoparticles. Pancreas, 2015, 44(2):250-259. (IF 2.738) [9] Chen SJ#, Zhang QB#, Zeng LJ#, Lian GD, Li JJ, Qian CC, Chen YZ, Chen YT*, Huang KH*. Distribution and clinical significance of TAMs in pancreatic ductal adenocarcinoma: A retrospective analysis in China. Curr Oncol, 2015, 22(1):e11-19. (IF 1.829) [10] Zeng L#, Guo Y#, Liang J#, Chen S, Peng P, Zhang Q, Su H, Chen Y*, Huang K*. Perineural Invasion and TAMs in Pancreatic Ductal Adenocarcinomas: Review of the Original Pathology Reports Using Immunohistochemical Enhancement and Relationships with Clinicopathological Features. J Cancer, 2014, 5(9):754-760. (IF 3.609) [11] Zhang QB, Chen YT, Lian GD, Qian CC, Chen SJ, Huang KH*. A combination of models for end-stage liver disease and cirrhosis-related complications to predict the prognosis of liver cirrhosis. Clin Res Hepatol Gastroenterol, 2012, 36(6):583-591. (IF 1.872) [12] Qian C#, Wang Y#, Chen Y, Zeng L, Zhang Q, Shuai X*, Huang K*. Suppression of pancreatic tumor growth by targeted arsenic delivery with anti-CD44v6 single chain antibody conjugated nanoparticles. Biomaterials, 2013, 34(26):6175-6184. (IF 8.387) [13] Wu Y, Wang W, Chen Y, Huang K*, Shuai X*, Chen Q, Li X, Lian G. The investigation of polymer-siRNA nanoparticle for gene therapy of gastric cancer in vitro. Int J Nanomedicine, 2010, 5:129-136. (IF 4.32) [14] Zeng L#, Li J#, Wang Y, Qian C, Chen Y, Zhang Q，Wu W，Lin Z，Liang J, Shuai X*, Huang Kaihong*. Combination of siRNA-directed Kras oncogene silencing and arsenic-induced apoptosis using a nanomedicine strategy for the effective treatment of pancreatic cancer. Nanomedicine, 2014, 10(2):463-472. (IF 5.671)